Siegfried (SIX: SFZN), a global Contract Development and Manufacturing Organization (CDMO), has announced the appointment of Eduardo Montanha as Chief Operating Officer and member of the Executive Committee, effective September 1, 2026. The appointment follows Siegfried's decision to combine the Chief Operating Officer roles for Drug Substances and Drug Products into one position, a structural change that supports the company's strategy to offer integrated end-to-end solutions across the pharmaceutical value chain.
Eduardo Montanha brings more than 20 years of international leadership experience in pharmaceutical and biopharmaceutical manufacturing. Most recently, he served as Executive Vice President, Head of Global Technical Operations & Quality at Fresenius Kabi, where he led an integrated global network of around 30 manufacturing sites across multiple regions. Earlier in his career, he held senior leadership positions at Takeda, Sandoz, Hexal, and Hoechst/Aventis, covering technical operations, quality, supply, and large-scale manufacturing networks.
With his strong track record in integrated operations, Eduardo Montanha will focus on further strengthening supply performance, operational efficiency and reliability across Siegfried's global network. Marcel Imwinkelried, Chief Executive Officer of Siegfried, commented: "I am very pleased to welcome Eduardo to Siegfried. He brings outstanding global operations and quality leadership experience and will play an important role in further enhancing supply performance, operational efficiency and reliability for our customers."
Eduardo Montanha holds a bachelor's degree in chemical engineering, a postgraduate qualification in Industrial Automation, and an MBA in Project Management. He brings extensive international leadership experience, having lived and worked across Europe and Latin America.
The appointment is a strategic move for Siegfried as it seeks to streamline its operations and offer more comprehensive services to its pharmaceutical clients. By combining the COO roles, the company aims to improve coordination between drug substance and drug product manufacturing, reducing lead times and enhancing quality control. This integration is critical as pharmaceutical companies increasingly seek CDMOs that can manage complex supply chains and provide seamless services from development to commercial production.
Siegfried's global footprint includes 16 sites in Switzerland, Germany, Spain, France, Malta, the USA, Australia and China. In 2025, the company achieved sales of CHF 1,327.8 million and employed more than 3,800 people. The company is publicly listed on the SIX Swiss Exchange (SIX: SFZN).
For more information, visit the original release on NewMediaWire.
